This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Y's Therapeutics, Inc.
Drug Names(s): YS-110, YSCMA
Description: YS110 is a humanized anti-CD26 monoclonal antibody.
Y's Therapeutics and Kissei
In September 2009, Y's Therapeutics and Kissei announced an exclusive licensing agreement in Japan to develop and commercialize YSCMA, a humanized anti-CD26 monoclonal antibody. Under the terms of this agreement, Kissei will develop and commercialize YSCMA for the treatment of malignant mesothelioma in Japan.
Partners: Kissei Pharmaceutical Co., Ltd
Pink Sheet Weekly Trademark Review Dec. 15, 2015
Pink Sheet Weekly Trademark Review Nov. 4, 2014
Pink Sheet Weekly Trademark Review Aug. 19, 2014
Pink Sheet Weekly Trademark Review Aug. 26, 2014
Additional information available to subscribers only: